Evidence map›Paper›PMID 41361522›Full record

ArticleNature microbiology2026

Surface expression of antitoxin on engineered bacteria neutralizes genotoxic colibactin in the gut.

Shaobo Yang, Zongqi Wang, Chengyuan Fang, Mengdi Yang, Saleh Khawaled, Shanna Bonanno, Neel S Joshi, Yun Wei, Ke Zhang, Valeria Márquez-Pellegrin and 13 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Shaobo Yang *Department of Bioengineering, Northeastern University, Boston, MA, USA.ORCID http://orcid.org/0009-0006-5257-6775
Zongqi Wang *Department of Biomedical Engineering, College of Engineering and School of Medicine, University of Michigan, Ann Arbor, MI, USA.
Chengyuan FangDepartment of Biomedical Engineering, College of Engineering and School of Medicine, University of Michigan, Ann Arbor, MI, USA.
Mengdi YangDepartment of Bioengineering, Northeastern University, Boston, MA, USA.
Saleh KhawaledKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Shanna BonannoDepartment of Bioengineering, Northeastern University, Boston, MA, USA.
Neel S JoshiDepartment of Bioengineering, Northeastern University, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8236-3566
Yun WeiDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, MA, USA.
Ke ZhangDepartment of Bioengineering, Northeastern University, Boston, MA, USA.
Valeria Márquez-PellegrinDepartment of Bioengineering, Northeastern University, Boston, MA, USA.
Ming GuanDepartment of Bioengineering, Northeastern University, Boston, MA, USA.
Songqi ZhangDepartment of Bioengineering, Northeastern University, Boston, MA, USA.
Anna Clara BaderDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ningyuan YeDepartment of Biomedical Engineering, College of Engineering and School of Medicine, University of Michigan, Ann Arbor, MI, USA.
Amber E HaleyDepartment of Biomedical Engineering, College of Engineering and School of Medicine, University of Michigan, Ann Arbor, MI, USA.
Michael K DameDivision of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0003-3760-1654
Jason R SpenceDepartment of Biomedical Engineering, College of Engineering and School of Medicine, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0001-7869-3992
Xuesong HeDepartment of Microbiology, ADA Forsyth Institute, Somerville, MA, USA.ORCID http://orcid.org/0000-0002-3333-9188
James G FoxDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-9307-6116
Ömer H YilmazKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-7577-4612
Yatrik M ShahDepartment of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-2487-4816
Rizwan RomeeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9077-4736
Jiahe LiDepartment of Biomedical Engineering, College of Engineering and School of Medicine, University of Michigan, Ann Arbor, MI, USA. jiaheli@umich.edu.ORCID http://orcid.org/0000-0002-9889-8546

Funding

Control of iron absorption by intestinal HIF2 in iron and hematological disordersR01DK095201 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHAH, YATRIK M · 2012 to 2025
$5.7M
The role of HIF2alpha in colon carcinogenesisR01CA148828 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHAH, YATRIK M · 2010 to 2025
$5.2M
Understanding and Harnessing Microbial Reprogramming to Combat Carcinogenic Colibactin in Colorectal CancerR01CA303150 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LI, JIAHE, SHAH, YATRIK M · 2025 to 2025
$2.9M
Enzymatic and genetic strategies for targeting disease-associated microbial metabolitesDP2GM154019 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jiahe Li · 2023 to 2026
$2.3M
Targeting a human gut bacterial genotoxin via engineered commensal bacteriaR01CA299955 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jiahe Li, Omer Yilmaz · 2025 to 2026
$1.2M
Division of Cancer Prevention, National Cancer Institute (NCI Division of Cancer Prevention) R01CA299955NCI NIH HHS R01 CA148828NCI NIH HHS R01 CA299955NCI NIH HHS R01 CA303150NIDDK NIH HHS R01 DK095201NIGMS NIH HHS DP2 GM154019United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (CDMRP) W81XWH-21-1-0324U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) DP2GM154019-01
6 · The paper itself

Abstract

Colibactin, a metabolite produced by gut bacteria carrying the polyketide synthase (pks) island, is associated with host genotoxicity and tumorigenesis. However, no Food and Drug Administration-approved therapeutics directly target colibactin. Here we show that expression of the intracellular colibactin self-resistance protein (ClbS) on the surface of engineered bacteria shields the host from genotoxic effects across multiple pks

Indexed as

Escherichia coliGastrointestinal MicrobiomeMutagensPeptidesPolyketidesAnimalsColitisColonic NeoplasmsDisease Models, AnimalDNA DamageHumansMicePolyketide SynthasescolibactinMutagensPeptidesPolyketidesPolyketide Synthases

Identifiers

PMID41361522
PMCPMC12833714

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.